Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $63.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective upped by Truist Financial from $56.00 to $63.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts have also recently commented on the company. HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Wedbush restated an “outperform” rating and set a $46.00 price target on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Stifel Nicolaus increased their price objective on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $64.43.

Dianthus Therapeutics Stock Up 0.2%

DNTH opened at $38.19 on Thursday. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -10.97 and a beta of 1.55. The firm has a 50 day moving average price of $40.69 and a 200-day moving average price of $32.08. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $45.46.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. As a group, analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This trade represents a 96.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 216,538 shares of company stock worth $8,283,175. 8.15% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Wellington Management Group LLP boosted its stake in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vestal Point Capital LP lifted its holdings in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. Braidwell LP bought a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $32,859,000. Polar Capital Holdings Plc bought a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $29,434,000. Finally, Fairmount Funds Management LLC grew its holdings in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after buying an additional 600,000 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.